Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Anti-androgen hormonal therapy for cancer and other diseases.

Student S, Hejmo T, Poterała-Hejmo A, Leśniak A, Bułdak R.

Eur J Pharmacol. 2020 Jan 5;866:172783. doi: 10.1016/j.ejphar.2019.172783. Epub 2019 Nov 8.

2.

Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.

Hanamura T, Niwa T, Nishikawa S, Konno H, Gohno T, Tazawa C, Kobayashi Y, Kurosumi M, Takei H, Yamaguchi Y, Ito K, Hayashi S.

Breast Cancer Res Treat. 2013 Jun;139(3):731-40. doi: 10.1007/s10549-013-2595-x. Epub 2013 Jun 19.

PMID:
23780684
4.

Hormonal therapy of prostate cancer.

Labrie F.

Prog Brain Res. 2010;182:321-41. doi: 10.1016/S0079-6123(10)82014-X.

PMID:
20541672
5.

Prolactin influences upon androgen action in male accessory sex organs.

Thomas JA, Keenan EJ.

Adv Sex Horm Res. 1976;2:425-70. Review.

PMID:
189591
6.

Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.

Traish AM.

Adv Exp Med Biol. 2017;1043:473-526. doi: 10.1007/978-3-319-70178-3_22. Review.

PMID:
29224108
7.

New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.

Amaral C, Varela C, Correia-da-Silva G, Tavares da Silva E, Carvalho RA, Costa SC, Cunha SC, Fernandes JO, Teixeira N, Roleira FM.

Biochimie. 2013 Nov;95(11):2097-106. doi: 10.1016/j.biochi.2013.07.023. Epub 2013 Aug 9.

PMID:
23933094
8.

Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.

Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P, Lin D, Taplin ME, Balk S, Ellis W, True L, Vessella R, Montgomery B, Blair IA, Penning TM.

J Steroid Biochem Mol Biol. 2013 Nov;138:281-9. doi: 10.1016/j.jsbmb.2013.06.014. Epub 2013 Jul 10.

9.

Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.

Zhu YS, Cai LQ, You X, Cordero JJ, Huang Y, Imperato-McGinley J.

J Androl. 2003 Sep-Oct;24(5):681-7.

10.

Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.

Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C.

Cancer Lett. 2017 Jul 1;397:133-143. doi: 10.1016/j.canlet.2017.03.022. Epub 2017 Mar 18.

PMID:
28323036
11.

Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.

Klus GT, Nakamura J, Li JS, Ling YZ, Son C, Kemppainen JA, Wilson EM, Brodie AM.

Cancer Res. 1996 Nov 1;56(21):4956-64.

12.

Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.

Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, Amory JK, Nelson PS, Matsumoto AM.

J Clin Endocrinol Metab. 2011 Feb;96(2):430-7. doi: 10.1210/jc.2010-1865. Epub 2010 Dec 22.

13.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952
14.

[Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].

Murez T, Basset V, Audenet F, Lebret T, Branchereau J.

Prog Urol. 2013 Oct;23 Suppl 1:S1-8. doi: 10.1016/S1166-7087(13)70040-X. Review. French.

PMID:
24314734
15.

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.

Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL.

Clin Cancer Res. 2005 Jul 1;11(13):4653-7.

16.

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.

BJU Int. 2008 May;101(9):1084-9. doi: 10.1111/j.1464-410X.2008.07509.x.

17.

Androgens induce divergent proliferative responses in human breast cancer cell lines.

Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD.

J Steroid Biochem Mol Biol. 1995 May;52(5):459-67.

PMID:
7748811
18.

Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.

Zhou Y, Otto-Duessel M, He M, Markel S, Synold T, Jones JO.

J Mol Endocrinol. 2013 Jun 29;51(1):143-53. doi: 10.1530/JME-13-0060. Print 2013.

20.

Basis for hormonal management of advanced prostate cancer.

Geller J.

Cancer. 1993 Feb 1;71(3 Suppl):1039-45.

PMID:
7679038

Supplemental Content

Support Center